Weight loss drugs may prevent heart attacks, stroke, and premature death
A groundbreaking study has unveiled that GLP-1 receptor agonists, a type of weight-loss drug, can decrease cardiovascular incidents by 13% in just under three years. These results remain consistent across different diabetes backgrounds, emphasizing long-lasting perks like diminished risks of heart attacks, strokes, and improved survival rates.
A groundbreaking study has unveiled that GLP-1 receptor agonists, a type of weight-loss drug, can decrease cardiovascular incidents by 13% in just under three years. These results remain consistent across different diabetes backgrounds, emphasizing long-lasting perks like diminished risks of heart attacks, strokes, and improved survival rates.
